Navigation Links
Antiviral therapy helps children at risk for post-transplant lymphoproliferative disease
Date:7/31/2008

The antiviral drug, valganciclovir, can lower the levels of Epstein-Barr virus in children with liver transplants, according to a new study. About half of young transplant recipients with detectable levels of the virus in their blood responded to a long course of the therapy, with 60 percent maintaining their response when they stopped taking the drug. These findings are in the August issue of Liver Transplantation, a journal by John Wiley & Sons. The article is also available online at Wiley Interscience (www.interscience.wiley.com).

Many pediatric liver recipients become infected with Epstein-Barr virus post-transplant, probably because the latent virus is in lymphocytes in the graft or in blood derivatives. Immunosuppressants taken to control rejection change the children's normal immune response to the virus, leading in some cases to uncontrolled lymphocyte B proliferation. Antiviral therapy is one possible way to address the danger of Epstein-Barr infection in transplant recipients.

Researchers, led by Paloma Jara of Madrid, studied the effects of valganciclovir in 47 pediatric transplant recipients with detectable Epsten-Barr DNA in their blood. They hoped to decrease the risk of post-transplant lymphoproliferative disease (PTLD) by blocking the viral replication that can lead to lymphocyte B proliferation.

After a median 8 months of treatment, EBV-DNA became undetectable in about half of the children who were asymptomatic at the start of the therapy, and no new cases of PTLD developed. In one child, who started the study with suspected PTLD, symptoms worsened over the course of the study. The safety profile was excellent, with no severe adverse events attributed to the drug.

The authors suggest that their results be interpreted with caution as they did not include a control group, and because the short timeframe for follow-up yielded no definitive conclusions about EBV outcomes.

Still, they concluded, "Valganciclovir has been shown safe in the current study and the population of children treated did not develop PTLD, warranting future trials to confirm a positive effect in the management of EBV infection."

In an accompanying editorial, Michael Green and George Mazariegos of the University of Pittsburgh, discuss their experience lowering immune suppression for patients with persistently high EBV loads, instead of using antiviral therapy.

"We have developed a relatively standardized approach to the presence of the high load carrier state which aims to gradually reduce immune suppression while carefully monitoring for any evidence of breakthrough rejection," they report.

"We agree that additional trials of valganciclovir are needed to establish a beneficial effect of this drug," they conclude.


'/>"/>

Contact: Sean Wagner
swagner@wiley.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop
2. Antivirals reduce deaths from flu in hospitalized patients
3. Antiviral Wont Improve Bells Palsy Outcome
4. BrainLAB Announces 510(k) FDA Clearance of Monte Carlo Dose Engine for Stereotactic Radiosurgery and Radiation Therapy
5. New therapy for HIV treatment
6. Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans
7. Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
8. CSHL scientists correlate enzyme expression levels with chemotherapy drug response
9. D-cycloserine may improve behavioral therapy treatment for anxiety
10. Tx Xchange Launches Web-Based Solution for Physical Therapy and Rehabilitation Providers to Address Demands of Healthcare Consumerism
11. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology: